SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States an…
$24.24-0.12%
报价 2026-11-06
市值
$1.09B
EV
$1.09B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -2.8%
$11.61$24.95
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.2x | -0.31 → -0.30 | — |
| FY+32028-12 | 1.4x | -0.31 → -0.16 | — |
毛利率 79% · TTM 收入 $221M · 基数 EPS -0.31（调整后）
电话会信号
辅助标签Q3 20262026-11-02
扩产需求加速盈利拐点供不应求
指引 维持
信心 5
分析师 4
“We expect over 20% revenue growth in Q4 and significant operating momentum entering 2027.”
原文引用（4）
- 扩产：we're pushing out more trades into the field as well as more inventory
- 需求加速：demand accelerated for our expanded INTRA platform from interventional spine physicians
- 盈利拐点：we expect strong revenue growth and continuing operating leverage to drive further margin expansion and move us towards GAAP profitability.
- 供不应求：we're really deploying additional surgical capacity out there in November and December
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| SIBNSI-BONE, Inc. | $1.09B | -0.1% | +16.2% | 79.3% | – | – | – | |
| BFLYButterfly Network, Inc. | $1.7B | +4.9% | +36.1% | 73% | – | – | – | 高增长 |
| INNVInnovAge Holding Corp. | $1.22B | -1.3% | +11.4% | 17.7% | 165.1x | 30.4x | 17.5x | |
| VREXVarex Imaging Corporation | $783M | -0.4% | +3.8% | 34.3% | 35.2x | 12.1x | – | |
| PACBPacific Biosciences of California, Inc. | $700.9M | -7.2% | +6.3% | 36% | – | – | – | |
| AQSTAquestive Therapeutics, Inc. | $453.1M | -1.4% | +7.4% | 58.4% | – | – | – | |
| OFIXOrthofix Medical Inc. | $318.1M | -11.8% | +4.9% | 69.6% | – | 5.7x | – | |
| CLPTClearPoint Neuro, Inc. | $275.7M | -1.0% | +45.1% | 62.6% | – | – | – | |
| AVXLAnavex Life Sciences Corp. | $106.6M | +3.6% | +55.9% | 0% | – | – | – | |
| 同行中位数 | – | – | +9.4% | 47.2% | 100.1x | 12.1x | 17.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $55.7M | $56M | $52.6M | $56.4M | $48.7M | $48.6M | $47.3M | $49M |
| Gross Margin | 79.3% | 79.5% | 79.8% | 79% | 79.8% | 79.8% | 79.7% | 79.1% |
| Operating Margin | -7.8% | -8.6% | -9.7% | -4.4% | -11.1% | -14.4% | -15.8% | -11.2% |
| Net Income | $-3.6M | $-4.1M | $-4.3M | $-1.6M | $-4.6M | $-6.2M | $-6.5M | $-4.5M |
| Diluted EPS | -0.08 | -0.09 | -0.1 | -0.04 | -0.11 | -0.14 | -0.15 | -0.11 |
| Operating Cash Flow | $5.9M | $777,000 | $-2.4M | $1.7M | $2.3M | $173,000 | $-4.9M | $1.2M |
研究材料
电话会纪要摘要
暂无纪要摘要。